LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Frequently asked questions
What sector does LENZ Therapeutics Inc (LENZ) operate in?
LENZ Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is LENZ Therapeutics Inc (LENZ) current stock price?
As of the latest data, LENZ Therapeutics Inc stock price is $3.15, with a previous close of $3.15. LENZ Therapeutics Inc gained $0.01 in the last trading session, representing a 0.16% increase.
What is LENZ Therapeutics Inc (LENZ) current market capitalization?
LENZ Therapeutics Inc market cap is approximately 98.97 million.
What is LENZ Therapeutics Inc (LENZ) Earnings Per Share (EPS)?
The trailing EPS is -$3.98, and the forward EPS is -$3.08.
What is LENZ Therapeutics Inc (LENZ) EBITDA?
LENZ Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -31.80 million.
Does LENZ Therapeutics Inc (LENZ) pay dividends?
No. LENZ Therapeutics Inc does not pay a dividend.
How did LENZ Therapeutics Inc (LENZ) perform in its most recent earnings report?
In the last report (June 30, 2026), LENZ Therapeutics Inc posted an EPS surprise of 15.7% and a revenue surprise of 130.76%.
When is LENZ Therapeutics Inc (LENZ) next earnings report?
LENZ Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is LENZ Therapeutics Inc (LENZ) beta (volatility) score?
LENZ Therapeutics Inc has a beta of 1.626, suggesting it is more volatile than the market.
